Shopping Cart
Remove All
Your shopping cart is currently empty
Concizumab
😃Good
Catalog No. T77373Cas No. 1312299-39-0
Alias NN 7415, mAb 2021
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, blocking its interaction with the FXa active site. Injections of Concizumab increase thrombin in blood, thereby preventing and treating hemophilia.
Concizumab
Concizumab
😃Good
Catalog No. T77373Alias NN 7415, mAb 2021Cas No. 1312299-39-0
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, blocking its interaction with the FXa active site. Injections of Concizumab increase thrombin in blood, thereby preventing and treating hemophilia.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $228 | In Stock | In Stock | |
| 5 mg | $589 | In Stock | In Stock | |
| 10 mg | $967 | - | In Stock | |
| 25 mg | $1,430 | - | In Stock | |
| 50 mg | $1,930 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:> 95%
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, blocking its interaction with the FXa active site. Injections of Concizumab increase thrombin in blood, thereby preventing and treating hemophilia. |
| In vitro | In a concentration-dependent manner, Concizumab increases the peak value of thrombin [1]. |
| In vivo | In cynomolgus monkeys, Concizumab (i.v./s.c.) blocked the interaction between TFPI and FXa active site [2]. |
| Synonyms | NN 7415, mAb 2021 |
| Reactivity | Human |
| Verified Activity | Immobilized Human TFPI Protein (Fc) at 2 μg/mL (30 μL/well) can bind Concizumab. The EC50 is 14.01 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TFPI |
| Molecular Weight | 145.76 kDa |
| Cas No. | 1312299-39-0 |
| Isotype | Human IgG4SP kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Concizumab | purchase Concizumab | Concizumab cost | order Concizumab | Concizumab in vivo | Concizumab in vitro | Concizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.